Unknown

Dataset Information

0

Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma.


ABSTRACT: Patients with glioblastoma have a very poor prognosis despite aggressive therapeutic strategies. Cytomegalovirus has been detected in >90% of glioblastoma tumors. This virus can affect tumor progression and may represent a novel glioblastoma therapy target. We report, here, a retrospective survival analysis of patients with secondary glioblastoma who were treated with the anti-viral drug valganciclovir at Karolinska University Hospital in Stockholm. We performed survival analyses of eight patients with secondary glioblastoma who were treated with a standard dose of valganciclovir as an add-on to second-line therapy after their disease progression to glioblastoma. Thirty-six patients with secondary glioblastoma admitted during the same time period who received similar treatment and care served as contemporary controls. The patients treated with valganciclovir showed an increased median overall survival after progression to glioblastoma compared with controls (19.1 versus 12.7 months, p = 0.0072). This result indicates a potential positive effect of valganciclovir in secondary glioblastoma, which is in agreement with our previous observation that valganciclovir treatment improves the outcomes of patients with newly diagnosed glioblastoma. Larger randomized studies are warranted to prove this hypothesis.

SUBMITTER: Stragliotto G 

PROVIDER: S-EPMC7599902 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma.

Stragliotto Giuseppe G   Pantalone Mattia Russel MR   Rahbar Afsar A   Söderberg-Nauclér Cecilia C  

Microorganisms 20200924 10


Patients with glioblastoma have a very poor prognosis despite aggressive therapeutic strategies. Cytomegalovirus has been detected in >90% of glioblastoma tumors. This virus can affect tumor progression and may represent a novel glioblastoma therapy target. We report, here, a retrospective survival analysis of patients with secondary glioblastoma who were treated with the anti-viral drug valganciclovir at Karolinska University Hospital in Stockholm. We performed survival analyses of eight patien  ...[more]

Similar Datasets

| S-EPMC6620640 | biostudies-literature
| S-EPMC8773484 | biostudies-literature
| S-EPMC4276952 | biostudies-literature
| S-EPMC8126706 | biostudies-literature
| S-EPMC8749852 | biostudies-literature
| S-EPMC6767870 | biostudies-literature
| S-EPMC7059389 | biostudies-literature
| S-EPMC3865973 | biostudies-other
| S-EPMC6494418 | biostudies-literature
| S-EPMC10906875 | biostudies-literature